tiprankstipranks
Advertisement
Advertisement

HK:1477 Stock Latest News

Ocumension grants new share options and awards to bolster talent retention
Company AnnouncementsOcumension grants new share options and awards to bolster talent retention
12d ago
1477
Ocumension Enrolls First Patient in China Phase III Trial for FDA-Approved Dry Eye Drug OT-211
PremiumCompany Announcements
Ocumension Enrolls First Patient in China Phase III Trial for FDA-Approved Dry Eye Drug OT-211
2M ago
1477
Ocumension Nearly Doubles Revenue in 2025 and Turns EBITDA Positive on Ophthalmic Portfolio Growth
PremiumCompany Announcements
Ocumension Nearly Doubles Revenue in 2025 and Turns EBITDA Positive on Ophthalmic Portfolio Growth
2M ago
1477
Ocumension Plans Board Refresh With New Independent Director After Wu’s Retirement
PremiumCompany Announcements
Ocumension Plans Board Refresh With New Independent Director After Wu’s Retirement
2M ago
1477
Ocumension Sets March Board Meeting to Approve 2025 Results and Mull Dividend
PremiumCompany Announcements
Ocumension Sets March Board Meeting to Approve 2025 Results and Mull Dividend
3M ago
1477
Ocumension Completes Patient Enrollment for Real-World Study of OT-703 in Hainan
PremiumCompany AnnouncementsOcumension Completes Patient Enrollment for Real-World Study of OT-703 in Hainan
4M ago
1477
Ocumension Increases Treasury Share Holdings to Nearly 21 Million
Premium
Company Announcements
Ocumension Increases Treasury Share Holdings to Nearly 21 Million
5M ago
1477
Ocumension Therapeutics Gains Approval for OT-702 in China
Premium
Company Announcements
Ocumension Therapeutics Gains Approval for OT-702 in China
6M ago
1477
Ocumension Therapeutics Reports Strong Revenue Growth Amid Product Expansion
PremiumCompany Announcements
Ocumension Therapeutics Reports Strong Revenue Growth Amid Product Expansion
9M ago
1477
Ocumension’s OT-301 Achieves Key Milestone in Phase III Trial
PremiumCompany Announcements
Ocumension’s OT-301 Achieves Key Milestone in Phase III Trial
9M ago
1477
Ocumension Therapeutics to Review Interim Results in Upcoming Board Meeting
PremiumCompany Announcements
Ocumension Therapeutics to Review Interim Results in Upcoming Board Meeting
10M ago
1477
Ocumension Therapeutics Updates Nomination Committee
PremiumCompany Announcements
Ocumension Therapeutics Updates Nomination Committee
11M ago
1477
Ocumension Therapeutics Announces Board Composition and Roles
PremiumCompany AnnouncementsOcumension Therapeutics Announces Board Composition and Roles
11M ago
1477
Ocumension Therapeutics Updates Nomination Committee Terms
Premium
Company Announcements
Ocumension Therapeutics Updates Nomination Committee Terms
11M ago
1477
Promising Outlook for Ocumension Therapeutics: Buy Rating Backed by Strategic Developments and Regulatory Milestones
Premium
Ratings
Promising Outlook for Ocumension Therapeutics: Buy Rating Backed by Strategic Developments and Regulatory Milestones
11M ago
Ocumension Therapeutics Revamps Share Option Scheme to Boost Employee Incentives
PremiumCompany Announcements
Ocumension Therapeutics Revamps Share Option Scheme to Boost Employee Incentives
11M ago
1477
Ocumension Therapeutics Successfully Passes All AGM Resolutions
PremiumCompany Announcements
Ocumension Therapeutics Successfully Passes All AGM Resolutions
11M ago
1477
Ocumension Therapeutics Gains Approval for Phase III Trial of Presbyopia Treatment in China
PremiumCompany Announcements
Ocumension Therapeutics Gains Approval for Phase III Trial of Presbyopia Treatment in China
12M ago
1477
Ocumension’s OT-703 Approved for Study in Hainan
PremiumCompany Announcements
Ocumension’s OT-703 Approved for Study in Hainan
1y ago
1477
Ocumension Therapeutics Announces 2025 Annual General Meeting
PremiumCompany AnnouncementsOcumension Therapeutics Announces 2025 Annual General Meeting
1y ago
1477
Ocumension Therapeutics Proposes Amendments to Optimize Operations
Premium
Company Announcements
Ocumension Therapeutics Proposes Amendments to Optimize Operations
1y ago
1477
Ocumension Therapeutics Reports Significant Revenue Growth and Strategic Advancements in 2024
Premium
Company Announcements
Ocumension Therapeutics Reports Significant Revenue Growth and Strategic Advancements in 2024
1y ago
1477

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >